AGN: Analysis & Opinions

  1. Valeant Eyes Bausch & Lomb

    May 28, 2013
    Canadian pharmaceutical company Valeant has made a name for itself through acquisitions. On May 27 it announced that ...
  2. Mixed 4Q at American Capital Agency - Analyst Blog

    February 08, 2013
    American Capital Agency Corp. (AGNC) reported mixed results in fourth quarter 2012. The company's net spread income ...
  3. AGN Earnings Miss but Guidance Tops - Analyst Blog

    February 05, 2013
    Allergan, Inc. (AGN) reported fourth quarter 2012 earnings of $1.15 per share, missing the Zacks Consensus Estimate ...
  4. Spectrum Acquires Apaziquone Rights - Analyst Blog

    February 04, 2013
    Spectrum Pharmaceuticals (SPPI) recently announced that it has regained development and commercial rights for ...
  5. Valeant Closes Natur Acquisition - Analyst Blog

    February 04, 2013
    Valeant Pharmaceuticals International, Inc. (VRX) recently closed the acquisition of Russia-based Natur Produkt ...
  6. Update on AGN's Acquisition of MAP - Analyst Blog

    February 01, 2013
    Allergan, Inc. (AGN) recently announced that it has commenced a cash tender offer to purchase all the shares of MAP ...
  7. "Retirement Savings Stocks" Yielding Up To 14%

    February 01, 2013
    We're calling them Retirement Savings Stocks -- 10 under-the-radar investments that can provide the cash needed to ...
  8. Favorable Ruling for Allergan - Analyst Blog

    January 29, 2013
    Allergan (AGN) received some positive news when the US Court of Appeals for the Federal Circuit ruled in its favor ...
  9. Allergan to Buy MAP Pharmaceuticals - Analyst Blog

    January 23, 2013
    In a bid to strengthen its position in the neurology and migraine specialty fields, Allergan, Inc. (AGN) recently ...
  10. Allergan's Botox Label Expanded - Analyst Blog

    January 21, 2013
    Allergan Inc. (AGN) recently received a major boost with the US Food and Drug Administration (FDA) approving Botox ...
  11. Acorda Provides Guidance - Analyst Blog

    January 08, 2013
    Acorda Therapeutics, Inc. (ACOR) recently disclosed unaudited sales of Ampyra (dalfampridine) extended release ...
  12. Pernix Acquires Cypress and Hawthorn - Analyst Blog

    January 07, 2013
    Pernix Therapeutics Holdings, Inc. (PTX) recently announced that it has completed the acquisition of Cypress ...
  13. Tough Times Ahead for Endo Health - Analyst Blog

    January 07, 2013
    Endo Health Solutions (ENDP) recently issued a disappointing outlook for 2013. The US-based diversified healthcare ...
  14. Abbott Spins Off Pharma Business - Analyst Blog

    January 03, 2013
    Abbott Laboratories (ABT) recently announced that the company has separated its research-based pharmaceuticals ...
  15. Neutral on Sanofi - Analyst Blog

    December 31, 2012
    We are maintaining our Neutral recommendation on Sanofi (SNY). The stock carries a Zacks #3 Rank (Hold) in the short ...
  16. Takeda Terminates Amylin Agreement - Analyst Blog

    December 31, 2012
    Takeda Pharmaceutical Company Limited (TKPYY) recently announced that it has mutually terminated its worldwide ...
  17. Acorda Completes Acquisition of Neuronex - Analyst Blog

    December 27, 2012
    Acorda Therapeutics, Inc. (ACOR) recently completed the acquisition of privately-held Neuronex, Inc. As per the ...
  18. Oncothyreon/Merck KGaA Drug Fails - Analyst Blog

    December 27, 2012
    Oncothyreon Inc. (ONTY) and its partner, Merck KGaA (MKGAY) recently presented disappointing data from a phase III ...
  19. Pfizer Signs a Couple of Deals - Analyst Blog

    December 26, 2012
    Pfizer (PFE) recently entered into two deals. While one deal was signed with biopharma company Halozyme ...
  20. Roche's Tamiflu Label Expanded - Analyst Blog

    December 24, 2012
    Switzerland based Roche (RHHBY) recently announced that the US Food and Drug Administration (FDA) has approved ...
Marketplace
Trading Center